Overview

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with Trifluridine/Tipiracil could increase the rate of cases with undetectable ct-DNA and therefore improve DFS in a population at high-risk of relapse.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Oncologico del Nord-Ovest
Collaborators:
Foundation Medicine
Servier
Treatments:
Capecitabine
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin
Trifluridine